847556-35-8Relevant academic research and scientific papers
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Page/Page column 49, (2014/07/08)
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kirl.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF
-
Page/Page column 59, (2010/11/08)
The present invention provides a compound represented by the formula: wherein R1 is an acyl group, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, a sulfur atom or the like, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.
Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors
Zask, Arie,Kaplan, Joshua,Du, XueMei,MacEwan, Gloria,Sandanayaka, Vincent,Eudy, Nancy,Levin, Jeremy,Jin, Guixian,Xu, Jun,Cummons, Terri,Barone, Dauphine,Ayral-Kaloustian, Semiramis,Skotnicki, Jerauld
, p. 1641 - 1645 (2007/10/03)
Potent and selective TACE and MMP inhibitors utilizing the diazepine and thiazepine ring systems were synthesized and evaluated for biological activity in in vitro and in vivo models of TNF-α release. Oral activity in the mouse LPS model of TNF-α release
